Biocytogen’s Subsidiary Eucure Biopharma and Chips...

BEIJING, China, February 27, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive l...

Biocytogen Announces FDA Clearance of IND Applicat...

BEIJING, China, December 19, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally dev...

First Patient Dosed in Phase 1/2 Trial Evaluating...

Beijing, China and San Diego, CA, November 22, 2022 - Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON...

ucure Biopharma, a Subsidiary of Biocytogen, Annou...

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials sponsored by Eucure Biopharma for pancreatic cancer and mela...

Eucure Biopharma, a Subsidiary of Biocytogen Pharm...

BEIJING, China and FORT LAUDERDALE, FL., Oct. 18, 2022 (BUSINESS WIRE) – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today that the company has...

US FDA Approval of IND for CTLA-4 Antibody YH001 f...

Beijing, China and San Diego, CA, August 29, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved t...